No Data
No Data
Trevi Therapeutics to Participate in Upcoming Investor and Healthcare Events
Two abstracts accepted for oral presentation at the 13th London International Cough SymposiumNEW HAVEN, Conn., July 2, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage bi
Here's Why We're Not Too Worried About Trevi Therapeutics' (NASDAQ:TRVI) Cash Burn Situation
Trevi Therapeutics Initiated at Buy by Rodman & Renshaw
Trevi Therapeutics Initiated at Buy by Rodman & Renshaw
Rodman & Renshaw Initiates Coverage On Trevi Therapeutics With Buy Rating, Announces Price Target of $7
Rodman & Renshaw analyst Brandon Folkes initiates coverage on Trevi Therapeutics (NASDAQ:TRVI) with a Buy rating and announces Price Target of $7.
Rodman & Renshaw Initiates Trevi Therapeutics(TRVI.US) With Buy Rating, Announces Target Price $7
Rodman & Renshaw analyst Elemer Piros initiates coverage on $Trevi Therapeutics(TRVI.US)$ with a buy rating, and sets the target price at $7.According to TipRanks data, the analyst has a success rate
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersVenus Concept (NASDAQ:VERO) stock rose 131.0% to $1.43 during Thursday's after-market session. The market value of their outstanding shares is at $9.0 million. Cyclacel Pharmaceuticals (NASDAQ:
Massinooo : Is this ticker good to trade?
TrytosaveabitOP Massinooo: It will be eventually! Im still looking for bottom?
Massinooo : I have it for 1.16 you think I should hold?
TrytosaveabitOP Massinooo: If you don’t mind averaging down some if need be? Im sorry! I just can’t say whether to buy or sell? I only say what I’m doing! I would hate to be responsible for someone losing! Grrr! Sorry but I’m rooting for you!
Massinooo : Totally understand bro. I’ll keep an eye on it after market opens and will decide. Thank you bro
View more comments...